Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended): Peripheral blood mononuclear cells (PBMC) comprising one or more suppressor T cells capable of decreasing graft rejection of a solid organ by a recipient made by the process comprising:
    a) isolating peripheral blood mononuclear cells (PBMC) from a recipient and an organ donor;
    b) irradiating T cell-depleted mononuclear cells from said organ donor PBMC; and
    c) combining *ex vivo* said recipient PBMC with said donor irradiated T cell-depleted mononuclear cells and a regulatory composition comprising TGF-β to induce one or more recipient suppressor T cells, wherein said suppressor T cells are CD4+CD25+ cells.

2. (Currently amended): A population of peripheral blood mononuclear cells (PBMC) comprising suppressor T cells capable of decreasing graft rejection of a solid organ by a recipient made by the process comprising:
    a) isolating peripheral blood mononuclear cells (PBMC) from a recipient and an organ donor;
    b) irradiating T cell-depleted mononuclear cells from said organ donor PBMC;
    c) combining *ex vivo* said recipient PBMC with said donor irradiated T cell-depleted mononuclear cells and a regulatory composition comprising TGF-β to induce a PBMC population comprising one or more recipient suppressor T cells; and
    d) wherein a recipient suppressor T cell population is produced by expanding said recipient suppressor T cells, and wherein said suppressor T cells are CD4+CD25+ cells.

3. (Previously presented): The PBMC comprising suppressor T cells according to Claim 1 or 2, wherein said regulatory composition further comprises cytokines selected from the group consisting of IL-2 and IL-15.

4. (Currently amended): The PBMC comprising suppressor T cells according to Claim 1 or 2, wherein prior to step (b) said recipient PBMC are enriched for CD4+ T cells.

5. (Previously presented): The PBMC comprising suppressor T cells according to Claim 4, wherein said CD4+ cells are enriched for naïve CD4+ T cells.

6. (Cancel)